Draft US FDA Guidance Outlines Heightened Expectations On Sterility Of Non-Sterile Drugs
Executive Summary
More testing expected after B. cepacia contamination of OTC liquid drug products, including for Rx drug products.
You may also be interested in...
US FDA Guidance On B. Cepacia Contamination Coming Soon, CDER Director Cavazzoni Says
Agency will provide guidance in wake of recent outbreaks of Burkholderia cepacia in non-sterile, water-based drug products.
B. Cepacia Hits ICUs Again, Raises Manufacturing Controls Questions
Another outbreak of B. cepacia at hospital intensive care units in multiple states implicates manufacturing and supply chain controls on aqueous non-sterile drug products, particularly for those marketed over the counter under OTC monographs.
FDA Email Alert: Next Day’s Manufacturing Volume Reporting Due Date Still Voluntary
Objections to 15 February reporting date established in draft guidance spurred rare last-minute notice assuring industry that it was a non-binding recommendation, not a requirement. Action reflects confusion that can arise in interpreting policy guidance.